Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MPO | P05164 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | AOC2 | O75106 | 2/20 | 0.37 |
| ▸ | CCNE1 | P24864 | 9/20 | 0.36 |
| ▸ | CDK2 | P24941 | 9/20 | 0.36 |
| ▸ | GSK3B | P49841 | 6/20 | 0.36 |
| ▸ | KDM6B | O15054 | 1/20 | 0.36 |
| ▸ | KDM4A | O75164 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2360121 | 0.79 | — | — | |
| SCHEMBL1650609 | 0.76 | — | — | |
| SCHEMBL2822798 | 0.74 | CYP4F2 (0.41) | KDM4ECCNE1CDK2GSK3BALDH1A1 | |
| SCHEMBL7603557 | 0.72 | MEN1 (0.33) | CCNE1CDK2GSK3BALDH1A1 | |
| SCHEMBL22311397 | 0.72 | CCNE1 (0.48) | CCNE1CDK2GSK3B | |
| SCHEMBL17984802 | 0.71 | — | — | |
| SCHEMBL159413 | 0.71 | — | — | |
| SCHEMBL31420810 | 0.70 | — | — | |
| SCHEMBL2829023 | 0.69 | VHL (0.44) | CYP1A2CYP3A4CYP2C9KDM4EAOC2 | |
| SCHEMBL2828248 | 0.68 | VHL (0.67) | KDM4ECCNE1CDK2GSK3BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4185575-B1 | HETEROARYL-METHYL SUBSTITUTED TRIAZOLES AS VASOPRESSIN RECEPTOR V1A ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2024-08-28 | — | — | EP | disclosed |
| CN-116234801-A | Heteroaryl-methyl substituted triazoles as vasopressin receptor V1A antagonists | 豪夫迈·罗氏有限公司 | 2023-06-06 | — | — | CN | disclosed |
| EP-4185575-A1 | HETEROARYL-METHYL SUBSTITUTED TRIAZOLES AS VASOPRESSIN RECEPTOR V1 A ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2023-05-31 | — | — | EP | disclosed |
| US-20230150995-A1 | HETEROARYL-METHYL SUBSTITUTED TRIAZOLES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-18 | — | — | US | disclosed |
| EP-1937688-B1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2010-08-11 | — | — | EP | disclosed |
| US-7507729-B2 | for the treatment of cognitive disorders, anxiety, schizophrenia, and Alzheimer's disease; ligands; GABA A alpha 5 receptor inhibitors; 3-bromo-10-chloro-6-(2-oxo-pyrrolidin-1-ylmethyl)-9H-imidazo[1,5-a][1,2,4]triazolo[1,5-d][1,4]benzodiazepine | HOFFMANN-LA ROCHE INC. (US) | 2009-03-24 | — | — | US | disclosed |
| EP-1937688-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007042421-A1 | IMIDAZO BENZODIAZEPINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2007-04-19 | — | — | WO | disclosed |
| US-20070082890-A1 | Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives | BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150995-A1 | HETEROARYL-METHYL SUBSTITUTED TRIAZOLES | CYP3A43, CYP3A4, CYP4B1 | CYP1A2 4/4885CYP3A4 2/4885CYP2C9 24/4885 |
| US-20070082890-A1 | Substituted imidazo-[1,5-a][1,2,4]triazolo[1,5-d][1,4] benzodiazepine derivatives | GABRA5, GABRA1, GABRA4 | CYP1A2 336/4885CYP3A4 205/4885CYP2C9 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.